Latest From Apotex Inc.
Health Canada asks ranitidine H2 blocker firms to halt sales until it gathers more information on NDMA contamination, which may form due to the drug’s instability. At least one marketer, Sandoz, also is recalling its ranitidine products in both Canada and US.
After receiving a CGT designation by the FDA for its generic version of Amicar, Amneal gets 180 days of exclusivity.
Court grants request to substitute Accord BioPharma for Apotex in Amgen infringement suit. Apotex says it has no plans to exit the biosimilar business.
Genentech reaches memorandum of understanding with JHL Biotech involving four biosimilars while continuing its suit against former employees; Amgen settlement with Coherus ended litigation entirely.
- Generic Drugs
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Apotex Inc.
- Senior Management
- Jeremy B Desai, PhD, Pres. & CEO
- Contact Info
Phone: (800) 268-4623
150 Signet Dr.
Toronto, M9L IT9
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.